penicillamine has been researched along with Parkinson Disease in 7 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa was effective, but the wearing-off phenomena were severe." | 1.29 | Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease. ( Kuno, S; Mizuta, E, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zaleska, B | 1 |
| Peters, L | 1 |
| Steventon, GB | 1 |
| Green, S | 1 |
| Sturman, S | 1 |
| Waring, RH | 1 |
| Williams, AC | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Canals, S | 1 |
| Casarejos, MJ | 1 |
| de Bernardo, S | 1 |
| Rodríguez-Martín, E | 1 |
| Mena, MA | 1 |
| Webster, DD | 1 |
| Mortimer, JA | 1 |
| Soyka, D | 1 |
| Tkachev, RA | 1 |
| Markova, ED | 1 |
| Gotovtseva, EV | 1 |
| Barkhatova, VP | 1 |
| Ivanova-Smolenskaia, IA | 1 |
1 review available for penicillamine and Parkinson Disease
| Article | Year |
|---|---|
[Progress in the treatment of degenerative diseases of the nervous system. Selected problems].
Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Humans; Huntington Disease; Lithium; Neostigmin | 1980 |
6 other studies available for penicillamine and Parkinson Disease
| Article | Year |
|---|---|
D-penicillamine metabolism in neurodegenerative diseases: an in vivo/in vitro sulphydryl methylation study.
Topics: Adult; Aged; Aged, 80 and over; Erythrocyte Membrane; Female; Humans; Male; Methylation; Methyltrans | 1994 |
Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease.
Topics: Absorption; Adult; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Male; Park | 1993 |
Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease.
Topics: Alkaloids; Aminoquinolines; Animals; Antioxidants; Apoptosis; Ascorbic Acid; Buthionine Sulfoximine; | 2001 |
Failure of L-dopa to relieve activated rigidity in Parkinson's disease.
Topics: Adult; Amantadine; Extrapyramidal Tracts; Hepatolenticular Degeneration; Humans; Levodopa; Male; Mid | 1977 |
[Syndrome involving the extrapyramidal motor systems and their drug treatment].
Topics: Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dihydroxyphenylalanine; gamma-Aminobutyric | 1974 |
[Principles of the pathogenetic therapy of congenital extrapyramidal diseases].
Topics: Adolescent; Adult; Atropine; Basal Ganglia Diseases; Chelating Agents; Chronic Disease; Dihydroxyphe | 1973 |